Last reviewed · How we verify
Sodium Chloride [3%] — Competitive Intelligence Brief
marketed
Electrolyte solution / Osmotic agent
Critical Care / Acute Medicine
Small molecule
Live · refreshed every 30 min
Target snapshot
Sodium Chloride [3%] (Sodium Chloride [3%]) — Fundacion Clinica Valle del Lili. Sodium chloride 3% is a hypertonic saline solution that draws fluid from intracellular and interstitial spaces into the vascular compartment through osmotic gradient.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sodium Chloride [3%] TARGET | Sodium Chloride [3%] | Fundacion Clinica Valle del Lili | marketed | Electrolyte solution / Osmotic agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Electrolyte solution / Osmotic agent class)
- Fundacion Clinica Valle del Lili · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sodium Chloride [3%] CI watch — RSS
- Sodium Chloride [3%] CI watch — Atom
- Sodium Chloride [3%] CI watch — JSON
- Sodium Chloride [3%] alone — RSS
- Whole Electrolyte solution / Osmotic agent class — RSS
Cite this brief
Drug Landscape (2026). Sodium Chloride [3%] — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-chloride-3. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab